Migracap-Plus Tablet SR is a sustained-release oral formulation containing a fixed combination of Propranolol (40mg) and Flunarizine (10mg). This tablet is specifically designed to treat acute and chronic migraine attacks, as well as other types of vascular headaches. Propranolol, a beta-blocker, contributes to the medication's analgesic and anti-inflammatory properties, while Flunarizine, a calcium-channel blocker, helps to reduce vasospasm and platelet aggregation. The sustained-release technology ensures a gradual and prolonged release of the active ingredients, providing a prolonged duration of therapeutic effect. Migracap-Plus Tablet SR is indicated for patients experiencing frequent and severe migraine attacks, often accompanied by symptoms such as nausea, vomiting, and photophobia. The recommended starting dose is one tablet once daily, with the option to increase the dose up to two tablets per day if necessary. As with any medication, patients should consult their healthcare provider before taking Migracap-Plus Tablet SR, especially those with a history of heart disease, hypertension, or respiratory disorders.